Shockwave for Pain Management

Substance P depletion in dorsal root ganglia C-fibers and A-delta fibers. CGRP reduction at peripheral terminals. KEY MECHANISM: Selective destruction of unmyelinated sensory nerve fibers — pivotal for long-lasting analgesia. Gate control theory and large-diameter fiber stimulation. Hyperstimulation analgesia altering pain neurotransmission. Pain reduction begins 2-5 minutes post-treatment, effects last 2-4 weeks. Critical: local anesthesia COMPROMISES the effect.

ESWT more effective than other treatments for MPS — lower pain levels, higher pain threshold, lower neck disability index. Focused ESWT serves as both treatment AND diagnostic tool for MTrPs. Diagnostic accuracy for low back: QL (96%), glut med (95%), glut min (92%). Combined with dry needling, manual therapy, exercise. Trapezius most studied muscle. Challenge: significant inconsistencies in protocols across literature.

Morton's neuroma: RCT evidence — significantly decreased VAS at 1 and 4 weeks. Note: neuroma diameter unchanged (symptom relief without structural change). Postherpetic neuralgia: randomized single-blind study showing benefit. Peripheral neuropathies including diabetic neuropathy: inspiring results but limited evidence, classified as emerging/experimental.

Focused ESWT: single session as effective as corticosteroid injection with effects persisting 3+ months. Radial ESWT: reduced pain, improved functional AND electrophysiological findings in mild-moderate CTS. Double-blind, placebo-controlled evidence available. Dose-dependent response demonstrated. Assessment: Boston Carpal Tunnel Questionnaire.

Three target areas for chronic LBP. (1) PARAVERTEBRAL: Radial/focused ESWT to paraspinal muscles reduces spasticity and connective tissue stiffness, stimulates NO synthesis for improved neuromuscular transmission. Particularly effective for MTrPs in quadratus lumborum (present in 91% of CLBP) and gluteus minimus (82%). Protocol: 0.10-0.25 mJ/mm², 2,000-4,000 impulses, 4-8 Hz, weekly × 3-5 sessions. (2) SI JOINT (15-30% of CLBP): Focused ESWT penetrates joint capsule, breaks intra-articular scar tissue, promotes collagen regeneration and neovascularization. Protocol: 0.20-0.35 mJ/mm², 2,000-3,000 impulses, weekly × 4-6 sessions. (3) FACET JOINT: 2025 RCT (Int J Surgery, 128 patients) — focused ESWT at 0.35 mJ/mm², 1,200 shocks/session (600/segment), 5 weekly sessions significantly reduced pain and improved function. 2023 meta-analysis (J Orthop Surg Res, 632 patients): ESWT superior to other interventions for CLBP pain relief. 2024 systematic review (Frontiers in Medicine): comprehensive analysis across all three target areas.

CDC guidelines recognize nonopioid therapies as effective for many acute pain types. ESWT provides documented chronic MSK pain relief — the primary driver of opioid prescriptions. Building a multimodal non-pharmacological program. Communicating with referring physicians. Outcome tracking for program validation. Positioning within broader pain management ecosystem.

CRPS evidence: very limited — one study of 30 patients with medial femoral condyle CRPS showed 76.7% satisfactory at 2 months, 80% at 6 months. No subsequent large-scale trials. ISMST experimental classification. Multi-disciplinary approach recommended. When to refer to pain management specialists.

Pain: VAS (100mm line), NRS (0-10). Upper extremity: DASH/QuickDASH (0-100), MCID ~10.2 points. Foot/ankle: FAAM, AOFAS. Knee: Lysholm, VISA-P. Achilles: VISA-A. Back: ODI. Carpal tunnel: Boston CTQ. Scars: POSAS. VAS MCID: ~15-20mm. Baseline assessment protocols, progress tracking intervals, discharge criteria. Pressure pain algometry for trigger points.